Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Position Lifted by Element Wealth LLC

Element Wealth LLC lifted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 394.8% during the fourth quarter, Holdings Channel reports. The firm owned 65,740 shares of the company’s stock after buying an additional 52,454 shares during the period. Element Wealth LLC’s holdings in Teva Pharmaceutical Industries were worth $686,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Harel Insurance Investments & Financial Services Ltd. increased its position in Teva Pharmaceutical Industries by 184,642.3% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 27,711,340 shares of the company’s stock valued at $282,656,000 after acquiring an additional 27,696,340 shares during the period. Sound Shore Management Inc CT acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $80,791,000. Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 14.4% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 27,059,540 shares of the company’s stock worth $276,000,000 after acquiring an additional 3,413,100 shares in the last quarter. FMR LLC boosted its stake in shares of Teva Pharmaceutical Industries by 3,553.8% during the 3rd quarter. FMR LLC now owns 2,564,339 shares of the company’s stock worth $26,156,000 after acquiring an additional 2,494,156 shares in the last quarter. Finally, Meitav Investment House Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 82.8% during the 4th quarter. Meitav Investment House Ltd. now owns 4,305,674 shares of the company’s stock worth $44,914,000 after acquiring an additional 1,950,500 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, CEO Richard D. Francis sold 74,530 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $13.15, for a total transaction of $980,069.50. Following the completion of the transaction, the chief executive officer now directly owns 87,125 shares in the company, valued at $1,145,693.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Richard D. Francis sold 74,530 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total value of $980,069.50. Following the sale, the chief executive officer now owns 87,125 shares of the company’s stock, valued at $1,145,693.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Amir Weiss sold 31,766 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at approximately $132,062.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 390,738 shares of company stock valued at $5,132,766. Corporate insiders own 0.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TEVA. Barclays raised their target price on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. The Goldman Sachs Group raised their target price on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Monday, February 5th. Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $10.00 to $14.00 in a research note on Tuesday, January 23rd. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price on the stock in a research report on Friday, March 8th. Finally, Piper Sandler raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $12.00 to $19.00 in a research report on Monday, February 12th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.78.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA traded up $0.13 during trading hours on Tuesday, hitting $13.01. 8,946,967 shares of the stock were exchanged, compared to its average volume of 10,616,944. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. The company has a market cap of $14.59 billion, a PE ratio of -27.40, a price-to-earnings-growth ratio of 1.54 and a beta of 1.05. The company’s fifty day simple moving average is $13.50 and its two-hundred day simple moving average is $11.30. Teva Pharmaceutical Industries Limited has a 1-year low of $7.09 and a 1-year high of $14.47.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.25. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. The company had revenue of $4.46 billion for the quarter, compared to analyst estimates of $3.97 billion. On average, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.28 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.